Northern Trust Corp Aligos Therapeutics, Inc. Transaction History

Northern Trust Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.35 - $1.07 $22 - $69	-65 Reduced 0.07%	91,950 $32,000
Q1 2024 May 14, 2024	BUY	$0.64 - $1.13 $24,350 - $42,993	38,047 Added 70.5%	92,015 $90,000
Q4 2023 Feb 13, 2024	BUY	$0.56 - $0.8 $8,185 - $11,693	14,617 Added 37.15%	53,968 $35,000
Q1 2023 May 15, 2023	BUY	$0.87 - $2.11 $5,869 - $14,236	6,747 Added 20.69%	39,351 $34,000
Q2 2022 Aug 12, 2022	SELL	$1.04 - $2.14 $165,591 - $340,737	-159,223 Reduced 83.0%	32,604 $39,000
Q1 2022 May 13, 2022	SELL	$2.08 - $12.2 $24,901 - $146,058	-11,972 Reduced 5.87%	191,827 $412,000
Q4 2021 Feb 08, 2022	BUY	$11.48 - $17.69 $63,002 - $97,082	5,488 Added 2.77%	203,799 $2.42 Million
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $295,727 - $359,662	20,297 Added 11.4%	198,311 $3.08 Million
Q2 2021 Aug 13, 2021	BUY	$20.3 - $33.6 $1.31 Million - $2.16 Million	64,374 Added 56.65%	178,014 $3.63 Million
Q1 2021 May 12, 2021	SELL	$19.1 - $34.94 $109,767 - $200,800	-5,747 Reduced 4.81%	113,640 $2.58 Million
Q4 2020 Feb 11, 2021	BUY	$13.2 - $32.74 $1.58 Million - $3.91 Million	119,387 New	119,387 $3.3 Million

253K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.